Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition

Journal of Chemical Information and Computer Sciences

Volumn 43, Issue 4, 2003, Pages 1308-1315

  Susnow, Roberta G ^a   Dixon, Steven L ^a,b  

^a Accelrys   (United States)

^b SCHRÖDINGER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITORS;

ACOUSTIC NOISE; DRUG PRODUCTS; STRUCTURE (COMPOSITION);

ENZYME INHIBITION;

CYTOCHROME P450 2D6; ENZYME INHIBITOR; ORGANIC COMPOUND;

ARTICLE; CHEMICAL MODEL; CHEMISTRY; CLASSIFICATION; COMPUTER AIDED DESIGN; DECISION TREE; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; FACTUAL DATABASE; HUMAN; MONTE CARLO METHOD; SENSITIVITY AND SPECIFICITY;

COMPUTER-AIDED DESIGN; CYTOCHROME P-450 CYP2D6; DATABASES, FACTUAL; DECISION TREES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MODELS, CHEMICAL; MONTE CARLO METHOD; ORGANIC CHEMICALS; SENSITIVITY AND SPECIFICITY;

EID: 0041698413     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci030283p     Document Type: Article

References (70)

1. Pharmaceutical Industry 2001 Profile; Pharmaceutical Research and Manufacturers of America: Washington, DC, 2001.
2. Farrell, G. C. Drug-Induced Liver Disease, 1st ed.; Churchill Livingstone: New York, 1994.
3. Michalets, E. L. Update: Clinically Significant Cytochrome P-450 Drug Interactions. Pharmacotherapy 1998, 18, 84-112.
4. Steiner, E.; Bertilsson, L.; Sawe, J.; Bertling, I.; Sjoqvist, F. Polymorphic Debrisoquin Hydroxylation in 757 Swedish Subjects. Clin. Pharmacol. Ther. 1988, 44, 431-435.
5. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual Variations in Human Liver Cytochrome P450 Enzymes Involved in the Oxidation of Drugs, Carcinogens, and Toxic Chemicals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
6. Parkinson, A. Biotransformation of Xenobiotics. In Casarett and Doull's Toxicology: The Basic Science of Poisons; Klaassen, C. D., Ed.; McGraw-Hill: New York, 1996; pp 113-186.
7. Slaughter, R. L.; Edwards, D. J. Recent Advances: The Cytochrome P450 Enzymes. Ann. Pharmacother. 1995, 29, 619-624.
8. Hamelin, B. A.; Bouayad, A.; Drolet, B.; Gravel, A.; Turgeon, J. In vitro Characterization of Cytochrome P450 2D6 Inhibition by Classic Histamine H1 Receptor Antagonists. Drug Metab. Dispos. 1998, 26, 536-539.
9. Spina, E.; Avenosa, A.; Scordo, M. G.; Ancione, M.; Madia, A.; Gatti, G.; Perucca, E. Inhibition of Risperidone Metabolism by Fluoxetine in Patients with Schizophrenia: a Clinically Relevant Pharmacokinetic Drug Interaction. J. Clin. Psychopharmacol. 2002, 22, 419-423.
10. Abdel-Rahman, S. M.; Gotschall, R. R.; Kauffman, R. E.; Leeder, J. S.; Reams, G. L. Investigation of Terbinafine as a CYP2D6 Inhibitor in vivo. Clin. Pharmacol. Ther. 1999, 65, 465-472.
11. Kumar, G. N.; Rodrigues, A. D.; Buko, A. M.; Dinssen, J. F. Cytochrome P450-mediated Metabolism of the HIV-1 Protease Inhibitor Ritonavir (ABT-538) in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1996, 277, 423-431.
12. Dixon, S. L.; Villar, H. O. Investigation of Classification methods for the Prediction of Activity in Diverse Chemical Libraries. J. Comput.-Aided Mol. Design 1999, 13, 533-545.
13. Nogrady, T. Medicinal Chemistry: A Biochemical Approach, 2nd ed.; Oxford University Press: New York, 1988.
14. Strobl, G. R.; von Kruedener, S.; Steockigt, J.; Guengerich, F. P.; Wolff, T. Development of a Pharmacophore for Inhibition of Human Liver Cytochrome P-450 2D6: Molecular Modeling and Inhibition Studies. J. Med. Chem. 1993, 36, 1136-1145.
15. Vickers, A. E. M.; Sinclair, J. R.; Zollinger, M.; Heitz, F.; Glanzel, U.; Johanson, L.; Fischer, V. Multiple Cytochrome P-450s Involved in the Metabolism of Terbinfine Suggest a Limited Potential for Drug-Drug Interactions. Drug Metab. Dispos. 1999, 27, 1029-1038.
16. Otton, S. V.; Ball, S. E.; Cheung, S. W.; Inaba, T.; Rudolph, R. L.; Sellers, E. M. Venlafaxine Oxidation in vitro is Catalyzed by CYP2D6. Br. J. Clin. Pharmacol. 1996, 41, 149-156.
17. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three and Four-Dimensional-Quantitative Structure Activity Relationship (3D/4D-QSAR) Analysis of CYP2D6 Inhibitors. Pharmacogenetics 1999, 9.
18. Rodrigues, A. D.; Roberts, E. M. The in vivo Interaction of Dexmedetomidine with Human Liver Microsomal Cytochrome P4502D6 (CYP2D6). Drug Metab. Dispos. 1997, 25, 651-655.
19. de Groot, M. J.; Bijloo, G. J.; Hansen, K. T.; Vermeulen, N. P. E. Computer Prediction and Experimental Validation of Cytochrome P4502D6-Dependent Oxidation of GBR 12909. Drug Metab. Dispos. 1995, 23, 667-669.
20. Desta, Z.; Kerbusch, T.; Soukhova, N.; Richard, E.; Ko, J.-W.; Flockhart, D. A. Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide. J. Pharmacol. Exp. Ther. 1998, 285, 428-437.
21. Shin, J.-G.; Soukhova, N.; Flockhart, D. A. Effect of Antipsychotic Drugs on Human Liver Cytochrome P-450 (CYP) Isoforms in vitro: Preferred Inhibition of CYP2D6. Drug Metab. Dispos. 1999, 27, 1078-1084.
22. Hiroi, T.; Ohishi, N.; Imaoka, S.; Yabusaki, Y.; Fukui, H.; Funae, Y. Mepyramine, a Histamine HI Receptor Antagonist, Inhibits the Metabolic Activity of Rat and Human P450 2D Forms. J. Pharmacol. Exp. Ther. 1995, 272, 939-944.
23. Oback, R. S. Inhibition of Human Cytochrome P450 Enzymes by Constituents of St. John's Wort, an Herbal Preparation Used in the Treatment of Depression. J. Pharmacol. Exp. Ther. 2000, 294, 88-95.
24. Ball, S. E.; Ahern, D.; Scatina, J.; Kao, J. Venlafaxine: in vitro Inhibition of CYP2D6-Dependent Imipramine and Desipramine Metabolism; Comparative Studies with Selected SSRIs, and Effects on Human Hepatic CYP3A4, CYP2C9 and CYP1A2. Br. J. Clin. Pharmacol. 1997, 43, 619-626.
25. Bapiro, T. E.; Egnell, A.-C.; Hasler, J. A.; Masimirembwa, C. M. Application of Higher Throughput Screening (HTS) Inhibition Assays to Evaluate the Interaction of Antiparasitic Drugs with Cytochrome P450s. Drug Metab. Dispos. 2001, 29, 30-35.
26. Ebner, T.; Eichelbaum, M. The Metabolism of Aprindine in Relation to the Sparteine/Debrisoquine Polymorphism. Br. J. Clin. Pharmacol. 1993, 35, 426-430.
27. Wienkers, L. C.; Allievi, C.; Hauer, M. J.; Wynalda, M. A. Cytoohrome P-450-Mediated Metabolism of the Individual Enantiomers of the Antidepressant Agent Reboxetine in Human Liver Microsomes. Drug Metab. Dispos. 1999, 27, 1334-1340.
28. Ko, J. W.; Desta, Z.; Soukhova, N. V.; Tracy, T.; Flockhart, D. A. In vitro Inhibition of the Cytochrome P450 (CYP450) System by the Antiplatelet Drug Ticlopidine: Potent Effect on CYP2C19 and CYP2D6. Br. J. Clin. Pharmacol. 2000, 49, 343-351.
29. Wu, D.; Otton, S. V.; Proule, B. A.; Busto, U.; Inaba, T.; Kalow, W.; Sellers, E. M. Inhibition of Human Cytochrome P450 2D6 (CYP2D6) by Methadone. Br. J. Clin. Pharmacol. 1993, 35, 30-34.
30. Fischer, V.; Vogels, B.; Maurer, O.; Tynes, R. E. The Antipsychotic Clozapine is Metabolized by the Polymorphic Human Microsomal and Recombinant Cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 1992, 200, 1355-1360.
31. Von Moltke, L. L. D. J. G.; Cotreau-Bibbo, M. M.; Duan, S. X.; Harmatz, J. S.; Jerold, S.; Shader, R. I. Inhibition of Desipramine Hydroxylation in vitro by Serotonin-reuptake-inhibitor Antidepressants, and by Quinidine and ketoconazole: a Model System to Predict Drug Interactions in vivo. J Pharmacol. Exp. Ther. 1994, 268, 1278-1283.
32. Prakash, C.; Kamel, A.; Cui, D.; Whalen, R. D.; Miceli, J. J.; Tweedie, D. Identification of the Major Human Liver Cytochrome P450 Isoform(s) Responsible for the Formation of the Primary Metabolites of Ziprasidone and Prediction of Possible Drug Interactions. Br. J. Clin. Pharmacol. 2000, 49, 35S-42S.
33. Voorman, R. L.; Payne, N. A.; Wienkers, L. C.; Hauer, M. J.; Sanders, P. E. Interaction of Delavirdine with Human Liver Microsomal Cytochrome P450: Inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab. Dispos. 2001, 29, 41-47.
34. Grace, J. M.; Kinter, M. T.; MacDonald, T. L. Atypical Metabolism of Deprenyl and its Enantiomer, (S)-(+), a-Dimethyl-N-Propynylphen-ethylamine, by Cytochrome P450 2D6. Chem. Res. Toxlcol. 1994, 7, 286-290.
35. Schmider, J.; Greenblatt, D. J.; von Moltke, L. J.; Harmatz, J. S.; Shader, R. I. Inhibition of Cytochrome P450 by Nefazodone in vitro: Studies of Dextromethorphan O- and N-demethylation. Br. J. Clin. Pharmacol 1996, 41, 339-343.
36. Jaruratanasirikul, S.; Hortiwakul, R. The Inhibitory Effect of Amiodarone and Desethylamiodarone on Dextromethorphan O-demethylation in Human and Rat Liver Microsomes. J. Pharm. Pharmacol. 1994, 46, 933-935.
37. Tran, A.; Rey, E.; Pons, G.; Rousseau, M.; d'Athis, P.; Olive, G.; Mather, G. G.; Bishop, F. E.; Wurden, C. J.; Labroo, R.; Trager, W. F.; Kunze, K. L.; Thummel, K. E.; Vincent, J. C.; Gillardin, J.-M.; Lepage, F.; Levy, R. H. Influence of Stiripentol on Cytochrome P450-Mediated Metabolic Pathways in Humans: in vitro and in vivo Comparison and Calculation of in vivo Inhibition Constants. Clin. Pharmacol. Ther. (St. Louis) 1997, 62, 490-504.
38. Lillibridge, J. H.; Liang, B. H.; Kerr, B. M.; Webber, S.; Quart, B.; Shetty, B. V.; Lee, C. A. Characterization of the Selectivity and Mechanism of Human Cytochrome P450 Inhibition by the Human Immunodeficiency Virus-Protease Inhbitor Nelfinavir Mesylate. Drug Metab. Dispos. 1998, 26, 609-616.
39. Desta, Z.; Soukhova, N. V.; Flockhart, D. A. Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother. 2001, 45, 382-392.
40. McKillop, D.; Back, D. J.; McCormick, A. D.; Evans, J. A.; Tjia, J. Preclinical and in vitro Assessment of the Potential of D0870, an Antifungal Agent, for Producing Clinical Drug Interactions. Xenobiotica 1999, 29, 395-408.
41. Destra, Z.; Wu, G. M.; Morocho, A. M.; Flockhart, D. A. The Gastroprokinetic and Antiemetic Drug Metoclopramide Is a Substrate and Inhibitor of Cytochrome P450 2D6. Drug Metab. Dispos. 2002, 30, 336-343.
42. Nakajima, M.; Ohyama, K.; Nakamura, S.; Shimada, N.; Yamazaki, H.; Yokoi, T. Inhibitory Effects of Azelastine and its Metabolites on Drug Oxidation Catalyzed by Human Cytochrome P4050 Enzymes. Drug Metab. Dispos. 1999, 27, 792-797.
43. Halliday, R. C.; Jones, B. C.; Smith, D. A.; Kitteringham, N. R.; Park, B. K. An Investigation of the Interaction between Halofantrine, CYP2D6 and CYP3A4: Studies with Human Liver Microsomes and Heterologous Enzyme Expression Systems. Br. J. Clin. Pharmacol. 1995, 40, 369-378.
44. Zhang, W.; Ramamoorthy, Y.; Kilicarslan, T.; Nolte, H.; Tyndale, R. F.; Sellers, E. M. Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives. Drug Metab. Dispos. 2002, 30, 314-318.
45. Nakajima, M.; Yoshida, R.; Shimada, N.; Yamazaki, H.; Yokoi, T. Inhibition and Inactivation of Human Cytochrome P450 Isoforms by Phenethylisothiocyanate. Drug Metab. Dispos. 2001, 29, 1110-1113.
46. Vickers, A. E. M.; Zollinger, M.; Dannecker, R.; Tynes, R.; Heitz, F.; Fischer, V, In vitro Metabolism of Tegaserod in Human Liver and Intestine: Assessment of Drug Interactions. Drug Metab. Dispos. 2001, 29, 1269-1276.
47. Asano, T.; Kushida, H.; Sadakane, C.; Ishihar, K.; Wakui, Y.; Yangisawa, T.; Kimura, M.; Kamei, H.; Yoshida, T. Metabolism of Ipecac Alkaloids Cephaeline and Emetine by Human Hepatic Microsomal Cytochrome P450s and their Inhibitory Effects on P450 Enzyme Activities. Biol. Pharm. Bull. 2001, 24, 678-682.
48. Martinez, C.; Agundez, J. A.; Gervasini, G.; Martin, R.; Benitz, J. Tryptamine: A Possible Endogenous Substrate for CYP2D6. Pharmacogenetcs 1997, 7, 85-93.
49. Ring, B. J.; Binkley, S. N.; Vandenbranden, M.; Wrighton, S. A. In vitro Interaction of the Antipsychotic Agent Olanzapine with Human Cytochrome P450 CYP2C9, CYP2C19, CYP2D6, and CYP3A. Br. J. Clin. Pharm. 1996.
50. Jacobsen, W.; Christians, U.; Benet, L. Z. In vitro Evaluation of the Disposition of a Novel Cysteine Protease Inhibitor. Drug Metab. Dispos. 2000, 28, 1343-1351.
51. Fischer, V.; Johanson, L.; Heitz, F.; Tullman, R.; Graham, E.; Bladeck, J.-P.; Robinson, W. T. The 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor Fluvastatin: Effect on Human Cytochrome P-450 and Implications for Metabolic Drug Interactions. Drug Metab. Dispos. 1999, 27, 410-416.
52. Prueksaritanont, T.; Gorhan, L. M.; Ma, B.; Liu, L.; Yu, X.; Zhao, J. J.; Slaughter, D. E.; Arison, B. H.; Vyas, K. P. In vitro Metabolism of Simvastatin in Humans [SET] Identification of Metabolizing Enzymes and Effect of the Drug on Hepatic P450s. Drug Metab. Dispos. 1997, 25, 1191-1199.
53. Walker, D. K.; Alabaster, C. T.; Congrave, G. S.; Hargreaves, M. B.; Hyland, R. J.; Jones, B. C.; Reed, L. J.; Smith, D. A. Significance of Metabolism in the Disposition and Action of the Antidysrythmic Drug, Dofetilide. In vitro Studies and Correlation with in vivo Data. Drug Metab. Dispos. 1996, 24, 447-455.
54. Nicolas, J.-M.; Collart, P.; Gerin, B.; Mather, G.; Trager, W.; Levy, R.; Roba, J. In vitro Evaluation of Potential Drug Interactions with Levetiracetam, a New Antiepileptic Agent. Drug Metab. Dispos. 1999, 27, 250-254.
55. Kharasch, E. D.; Hankins, D. C.; Jubert, C. T.; Thummel, K. E.; Taraday, J. K. Lack of Single-Dose Disulfiram Effects on Cytochrome P-450 2c9, 2C19, 2D6, and 3A4 Activities: Evidence for Specificity toward P-450 2E1. Drug Metab. Dispos. 1999, 27, 717-723.
56. Robertson, P.; Decory, H. H.; Madan, A.; Parkinson, A. In vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil. Drug Metab. Dispos. 2000, 28, 664-671.
57. Erickson, D. A.; Mather, G.; Trager, W. F.; Levy, R. H.; Keirns, J. J. Characterization of the in vitro Biotransformation of the HIV-1 Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450. Drug Metab. Dispos. 1999, 27, 1488-1495.
58. Grimm, S. W.; Dyroff, M. C. Inhibition of Human Drug Metabolizing Cytochromes P450 by Anastrozole, a Potent and Selective Inhibitor of Aromatase. Drug Metab. Dispos. 1997, 25, 598-602.
59. Martinez, C.; Albet, C.; Agundez, J. A. G.; Herrero, E.; Carrillo, J. A.; Marquez, M.; Benitez, J.; Ortiz, J. A. Comparative in vitro and in vivo Inhibition of Cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-Receptor Antagonists. Clin. Phamacol. Ther. (St. Louis) 1999, 65, 369-376.
60. Callaghan, J. T.; Bergstrom, R. F.; Ptak, L. R.; Beasley, C. M. Olanzapine: Pharmacokinetic and Pharamcodynamic Profile. Clin. Pharmacokinet. 1999, 37, 177-193.
61. Nicolas, J.-M.; Whomsley, R.; Collart, P.; Roba, J. In vitro Inhibition of Human Liver Drug Metabolizing Enzymes by Second Generation Antihistamines. Chem.-Biol. Interact. 1999, 123, 63-79.
62. von Moltke, L. L.; Greenblatt, D. J.; Ciraulo, D. A.; Grassi, J. M.; Granada, B. W.; Duan, S. X.; Harmatz, J. S.; Shader, R. I. Appetite Suppressant Drugs as Inhibitors of Human Cytochromes P450: in vitro Inhibition of P450-2D6 by D- and L-Fenfluramine, but not Phentermine. J. Clin. Psychopharmacol. 1998, 18, 338-341.
63. von Moltke, L. L.; Greenblatt, D. J.; Granda, B. W.; Giancarlo, G. M.; Duan, S. X.; Daily, J. P.; Harmatz, J. S.; Shader, R. I. Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors. J. Clin. Pharmacol. 2001, 41, 85-91.
64. Sai, Y.; Dai, R.; Yang, T. J.; Krausz, K. W.; Gonzalez, F. J.; Gelboin, H. V.; Shou, M. Assessment of Specificity of Eight Chemical Inhibitors Using cDNA-Expressed Cytochromes P450. Xenobiotica 2000, 50, 327-343.
65. Breiman, L.; Friedman, J. H.; Olshen, R. A.; Stone, C. J. Classification and Regression Trees; Wadsworth International Group: Belmont, CA, 1984.
66. Hawkins, D. M.; Kass, G. V. In Topics in Applied Multivariate Analysis; Hawkins, D. H., Ed.; Cambridge University Press: Cambridge, 1982; pp 269-302.
67. Breiman, L. Bagging Predictors. Machine Learning 1996, 24, 123-140.
68. 2, ccM ed.; Accelrys: San Diego, CA, 2001.
69. Dixon, S. L.; Kenneth, M.; Merz, J. One-Dimensional Molecular Representations and Similarity Calculations: Methodology and Validation. J. Med. Chem. 2001, 44, 3795-3809.
70. S-PLUS 6.1 for Windows; Insightful Corporation: Seattle, WA, 2001.